Robert Hershberg - 17 Jun 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 17 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Jun 2026, 16:32:34 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Golightly, attorney-in-fact

Key filing fact

Robert Hershberg filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 22 Jun 2026.

Key facts

This page summarizes Robert Hershberg's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Jun 2026, 16:32.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001274139 Primary reporting owner

HERSHBERG ROBERT

Relationship: Director
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/ Jonathan Golightly, attorney-in-fact
Signature date: 22 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Award

Transaction value
Shares: +88,424
Change %: +120%
Price: $0.000000^*
Shares after: 162,156
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.